Corbus Pharmaceuticals Holdings (CRBP) EBT Margin (2015 - 2021)
Corbus Pharmaceuticals Holdings (CRBP) posted EBT Margin of 14257.07% for Q3 2021, down 16.74% on a QoQ basis from 12212.94% in Q2 2021, and down 1149635.0% year-over-year from N/an in Q3 2020.
Powered by 
Analysis
Corbus Pharmaceuticals Holdings (CRBP) EBT Margin (2015 - 2021) Analysis & Trends
Corbus Pharmaceuticals Holdings has reported EBT Margin for 7 years, with the latest figure at 14257.07% in Q3 2021.
- On a quarterly basis, EBT Margin fell 1149635.0% year-over-year to 14257.07% in Q3 2021; TTM through Jun 2022 was 45961.32%, a 4271029.0% decrease from a year earlier, with the FY2021 full-year figure at 6350.09%, down 323088.0% from the prior year.
- EBT Margin was 14257.07% for Q3 2021 at Corbus Pharmaceuticals Holdings, down from 12212.94% in the prior quarter.
- The five-year high for EBT Margin was 7.4% in Q2 2019, with the low at 14257.07% in Q3 2021.
- Average EBT Margin over 5 years is 3421.38%, with a median of 1404.73% recorded in 2018.
- The sharpest annual moves came in 2019 and 2020: EBT Margin jumped 142807 bps in 2019, then plunged 1332208 bps in 2020.
- Over 5 years, EBT Margin stood at 868.18% in 2017, then slipped by 4 bps to 900.03% in 2018, then decreased by 17 bps to 1050.66% in 2019, then sank by 201 bps to 3161.99% in 2020, then tumbled by 351 bps to 14257.07% in 2021.
- The last three EBT Margin figures came in at 14257.07% (Q3 2021), 12212.94% (Q2 2021), and 2383.82% (Q1 2021), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 27.53% |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | -131.41% |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 41.75% |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 35.61% |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 35.78% |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | -528.97% |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 13.77% |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 4.84% |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | -20,427.46% |
| 10 | Corbus Pharmaceuticals Holdings | 101.29 Mn | -61.98 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2021 | -14,257.07% |
| Jun 30, 2021 | -12,212.94% |
| Mar 31, 2021 | -2,383.82% |
| Dec 31, 2020 | -3,161.99% |
| Sep 30, 2020 | -2,760.72% |
| Jun 30, 2020 | -13,314.68% |
| Mar 31, 2020 | -1,690.26% |
| Dec 31, 2019 | -1,050.66% |
| Sep 30, 2019 | -957.76% |
| Jun 30, 2019 | 7.40% |
| Mar 31, 2019 | -1,388.79% |
| Dec 31, 2018 | -900.03% |
| Sep 30, 2018 | -1,341.09% |
| Jun 30, 2018 | -1,420.67% |
| Mar 31, 2018 | -1,226.96% |
| Sep 30, 2017 | -868.18% |
| Jun 30, 2017 | -2,080.69% |
| Mar 31, 2017 | -575.96% |
| Sep 30, 2016 | -718.06% |
| Jun 30, 2016 | -1,055.88% |